Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome

Shin, Sohee; Kim, Jung Ho; Jeon, Young‐Woo; Yoon, Jihyun; Yahng, Seung‐Ah; Lee, Sung‐Eun; Choi, Yunsuk; Kim, Dae-Young; Lee, Jung‐Hee; Lee, Seok; Kim, Hee-Je; Min, Chang‐Ki; Lee, Jong‐Wook; Lee, Kyoo‐Hyung; Min, Woo-Sung; Kim, Yoo-Jin; Lee, Je‐Hwan

doi:10.1016/j.bbmt.2014.10.031

Cited by 17 publications

(16 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supported by the results of ATG-based Haplo-SCT reported by other teams, showing better disease control in younger patients with less advanced diseases. [30][31][32][33][34] Our work has strengths and limitations. Its strengths include the relatively high number of patients compared with previous reports of PT-Cy Haplo-SCT for AML or MDS in the literature.…”

Section: Discussionmentioning

confidence: 99%

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

Devillier

Bramanti

Fürst

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases lacking HLA-identical donor. Although it provides low incidences of GVHD, the efficacy of Haplo-SCT is still questioned, especially for patients with myeloid malignancies. Thus, we analyzed 60 consecutive patients with refractory (n = 30) or high-risk CR (n = 30) AML or myelodysplastic syndromes (MDSs) who underwent PT-Cy Haplo-SCT. The median age was 57 years (22-73 years), hematopoietic cell transplantation comorbidity index was ⩾ 3 in 38 patients (63%) and Haplo-SCT was the second allogeneic transplantation for 10 patients (17%). Although most of patients received PBSC as graft source (n = 48, 80%), we found low incidences of grade 3-4 acute (2%) and severe chronic GVHD (4%). Among patients with high-risk CR diseases, 1-year non-relapse mortality, cumulative incidence of relapse, progression-free and overall survivals were 20%, 32%, 47% and 62%, respectively. In patients with refractory disease, corresponding results were 34%, 35%, 32% and 37%, respectively. We conclude that PT-Cy Haplo-SCT could provide promising anti-leukemic effect even in the setting of very advanced diseases. Thus, it represents a viable alternative for high-risk AML/MDS patients without HLA-identical donor.

show abstract

Section: Discussionmentioning

confidence: 99%

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

Devillier

Bramanti

Fürst

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…postoperatively at a total of 0.12 mg kg − 1 day − 1 ) and shortcourse methotrexate (10 mg/m 2 IV bolus injection on days +1, +3, +6 and +11) was used for GVHD prophylaxis in all patients, as described previously. 17 The dosage of tacrolimus was adjusted for each patient based on the plasma level to maintain a target dose of 8-12 ng/mL. The administration of tacrolimus was gradually reduced from day +90 after transplantation when there was no evidence of acute GVHD.…”

Section: Materials and Methods Patientsmentioning

confidence: 99%

Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation

Yoo

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

We analyzed the incidence and risk factors for ocular GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Korea. In this retrospective, noncomparative, observational study, 635 subjects were included who had at least 2 years of follow-up ophthalmological examinations after allo-HSCT from 2009 to 2012 at Seoul St Mary's Hospital, Seoul, Korea. The mean duration between allo-HSCT and onset of ocular GVHD was 225.5 ± 194.3 days. The adjusted incidence for acute ocular GVHD was 1.33% and that for chronic GVHD was 33.33%. In the multivariate analysis, preexisting diabetes mellitus (odds ratio (OR): 4.22, 95% confidence interval (CI): 1.66-10.72), repeated allo-HSCT (OR: 29.10, 95% CI: 1.02-8.28) and the number of organs that chronically developed GVHD by stage I (OR: 14.63, 95% CI: 9.81-21.84) increased risk of ocular GVHD. Careful monitoring of ocular GVHD is needed in patients with chronic GVHD in multiple organs and preexisting diabetes.

show abstract

“…1,2 In haploidentical transplantations where up to half of the HLA alleles may be mismatched, different conditioning and prophylactic regimens are being tested to minimize the risks for engraftment failure and GVHD. 3–6 …”

Section: Introductionmentioning

confidence: 99%

Maternal T-Cell Engraftment Interferes With Human Leukocyte Antigen Typing in Severe Combined Immunodeficiency

Liu¹,

Duffy²,

Bednarski

et al. 2016

Am J Clin Pathol

View full text Add to dashboard Cite

Objectives To report the laboratory investigation of a case of severe combined immune deficiency (SCID) with maternal T cell engraftment, focusing on the interference of human leukocyte antigen (HLA) typing by blood chimerism. Methods HLA typing was performed with three different methods, including sequence-specific primer (SSP), sequence-specific oligonucleotide (SSO), and Sanger sequencing on peripheral blood leukocytes and buccal cells from a 3-month-old male, and peripheral blood leukocytes from his parents. Short tandem repeat (STR) testing was performed in parallel. Results HLA typing of the patient’s peripheral blood leukocytes using the SSP method demonstrated three different alleles for each of the HLA-B and -C loci, with both maternal alleles present at each locus. Typing results from the patient’s buccal cells showed a normal pattern of inheritance for paternal and maternal haplotypes. STR enrichment testing of the patient’s CD3+ T lymphocytes and CD15+ myeloid cells confirmed maternal T cell engraftment, while the myeloid cell profile matched the patient’s buccal cells. Conclusion Maternal T cell engraftment may interfere with HLA typing in patients with SCID. Selection of the appropriate typing methods and specimens is critical for accurate HLA typing and immunological assessment prior to allogeneic hematopoietic stem cell transplantation.

show abstract

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome

Cited by 17 publications

References 61 publications

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation

Maternal T-Cell Engraftment Interferes With Human Leukocyte Antigen Typing in Severe Combined Immunodeficiency

Contact Info

Product

Resources

About